HemaSphere (May 2023)

Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria

  • Mareike Tometten,
  • Martin Kirschner,
  • Robert Meyer,
  • Matthias Begemann,
  • Insa Halfmeyer,
  • Margherita Vieri,
  • Kim Kricheldorf,
  • Angela Maurer,
  • Uwe Platzbecker,
  • Markus Radsak,
  • Philippe Schafhausen,
  • Selim Corbacioglu,
  • Britta Höchsmann,
  • C. Matthias Wilk,
  • Claas Hinze,
  • Jörg Chromik,
  • Michael Heuser,
  • Michael Kreuter,
  • Steffen Koschmieder,
  • Jens Panse,
  • Susanne Isfort,
  • Ingo Kurth,
  • Tim H. Brümmendorf,
  • Fabian Beier

DOI
https://doi.org/10.1097/HS9.0000000000000874
Journal volume & issue
Vol. 7, no. 5
p. e874

Abstract

Read online

Telomere biology disorders (TBD) result from premature telomere shortening due to pathogenic germline variants in telomere maintenance-associated genes. In adults, TBD are characterized by mono/oligosymptomatic clinical manifestations (cryptic TBD) contributing to severe underdiagnosis. We present a prospective multi-institutional cohort study where telomere length (TL) screening was performed in either newly diagnosed patients with aplastic anemia (AA) or if TBD was clinically suspected by the treating physician. TL of 262 samples was measured via flow-fluorescence in situ hybridization (FISH). TL was considered suspicious once below the 10th percentile of normal individuals (standard screening) or if below 6.5 kb in patients >40 years (extended screening). In cases with shortened TL, next generation sequencing (NGS) for TBD-associated genes was performed. The patients referred fell into 6 different screening categories: (1) AA/paroxysmal nocturnal hemoglobinuria, (2) unexplained cytopenia, (3) dyskeratosis congenita, (4) myelodysplastic syndrome/acute myeloid leukemia, (5) interstitial lung disease, and (6) others. Overall, TL was found to be shortened in 120 patients (n = 86 standard and n = 34 extended screening). In 17 of the 76 (22.4%) standard patients with sufficient material for NGS, a pathogenic/likely pathogenic TBD-associated gene variant was identified. Variants of uncertain significance were detected in 17 of 76 (22.4%) standard and 6 of 29 (20.7%) extended screened patients. Expectedly, mutations were mainly found in TERT and TERC. In conclusion, TL measured by flow-FISH represents a powerful functional in vivo screening for an underlying TBD and should be performed in every newly diagnosed patient with AA as well as other patients with clinical suspicion for an underlying TBD in both children and adults.